Literature DB >> 14613439

Physician perceptions of the use of medications for attention deficit hyperactivity disorder.

Karen M Stockl1, Tom E Hughes, Manal A Jarrar, Kristina Secnik, Amy R Perwien.   

Abstract

BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a prevalent mental health condition, occurring in 3% to 5% of school-aged children. Although stimulant medications are a recommended treatment for this disorder, physicians. views of these medications have not been systematically evaluated.
OBJECTIVE: This study examined physician-prescriber perceptions of using medications to treat ADHD symptoms in children or adolescents.
METHODS: A survey was developed with 4 physicians expert in treating ADHD in children. The survey was pilot-tested with a sample of 10 practicing physicians. A sample of 1,000 physicians, with a history of prescribing stimulant medications to children or adolescents, was randomly selected and mailed a 30-item survey. Items were rated on a 7-point response scale (strongly agree, agree, slightly agree, undecided, slightly disagree, disagree, strongly disagree).
RESULTS: A total of 365 physicians responded to the survey, for a 37% response rate. More than 92% of respondents strongly agreed or agreed that ADHD symptoms cause problems in pediatric patients and stimulants are effective in treating ADHD. The stimulant drug side effects of decreased appetite or weight loss, sleep disruption, and exacerbation of anxiety were a concern (strongly agree or agree response) for 32%, 50%, and 22% of physicians, respectively. Diversion of ADHD medication was a concern for 19% of respondents. Physicians reported that controlled medications for children or adolescents with ADHD are a burden for themselves (32% strongly agreed or agreed), for their staff (37% strongly agreed or agreed), and for parents (40% strongly agreed or agreed). Approximately 38% of physicians responded that they would prefer prescribing a nonstimulant medication with a U.S. Food and Drug Administration indication for treating children or adolescents instead of a stimulant medication, and 58% would prefer prescribing a noncontrolled medication that does not have evidence of abuse potential versus one that is controlled and has evidence of abuse potential.
CONCLUSION: Although physicians overwhelmingly perceive stimulant medications as being effective for treating ADHD symptoms in children or adolescents, many would prefer a nonstimulant medication. While many physicians consider the side effects of the stimulants easily managed, others are concerned about prescribing stimulants because of their side effects, risk of diversion, and administrative burden. The majority of physicians would prefer to prescribe a noncontrolled medication without abuse potential instead of a controlled medication to treat children or adolescents with ADHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613439     DOI: 10.18553/jmcp.2003.9.5.416

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  14 in total

1.  Complementary and alternative medicine in ADHD treatment: more soundly designed clinical trials needed.

Authors:  Rong-Wang Yang; Rong Li
Journal:  World J Pediatr       Date:  2019-01-28       Impact factor: 2.764

2.  Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance.

Authors:  Alison Looby; Mitch Earleywine
Journal:  Exp Clin Psychopharmacol       Date:  2011-08-29       Impact factor: 3.157

3.  Organisation of services for managing ADHD.

Authors:  D R Coghill
Journal:  Epidemiol Psychiatr Sci       Date:  2016-12-22       Impact factor: 6.892

4.  Variations in Physician Attitudes Regarding ADHD and Their Association With Prescribing Practices.

Authors:  R Christopher Sheldrick; Laurel K Leslie; Angie Mae Rodday; Susan K Parsons; Tully S Saunders; John B Wong
Journal:  J Atten Disord       Date:  2012-11-09       Impact factor: 3.256

5.  Willingness to use ADHD treatments: a mixed methods study of perceptions by adolescents, parents, health professionals and teachers.

Authors:  Regina Bussing; Mirka Koro-Ljungberg; Kenji Noguchi; Dana Mason; Gillian Mayerson; Cynthia W Garvan
Journal:  Soc Sci Med       Date:  2011-11-17       Impact factor: 4.634

6.  Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students.

Authors:  Dalissa R Sepúlveda; Lisl M Thomas; Sean Esteban McCabe; James A Cranford; Carol J Boyd; Christian J Teter
Journal:  J Pharm Pract       Date:  2011-11-17

7.  Preferences related to attention-deficit/hyperactivity disorder and its treatment.

Authors:  Kate Van Brunt; Louis S Matza; Peter M Classi; Joseph A Johnston
Journal:  Patient Prefer Adherence       Date:  2011-01-17       Impact factor: 2.711

Review 8.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

9.  Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.

Authors:  Arnie P Aldridge; Larry A Kroutil; Alexander J Cowell; Daniel B Reeves; David L Van Brunt
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.558

10.  Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.

Authors:  Rajasree Nair; Shannon B Moss
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.